Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Sanofi Profit Slumped 21% in Q3

By Pharmaceutical Processing | October 30, 2013

Sanofi said its net profit slumped by over a fifth in the third quarter as it continued to suffer the effects of overpaying for acquisitions and a painful restructuring.

Sanofi SA said its net profit fell 21 percent to 1.21 billion euros ($1.66 billion) in the July to September quarter, from 1.54 billion euros a year earlier.

In a statement, it warned that earnings for the full year would be “at the lower end” of previous guidance, with profit down around 10 percent before exchange rate fluctuations.

Third-quarter earnings included charges worth 689 million euros to account for the difference in what Sanofi paid to acquire companies such as Aventis, Genzyme and Merovial and what those assets are worth now. In the year to end-September, those charges amounted to 2.23 billion euros.

A restructuring charge of 71 million euros also weighed on third quarter earnings, Sanofi said. The company has spent over 5 billion euros on restructuring since 2008.

Sanofi says third-quarter sales fell 6.7 percent as the loss of patent protection for one-time blockbuster treatments such as Plavix and Lovenox continued to have an impact. A problem supplying some vaccines in the U.S. also hurt sales.

Earnings by Sanofi’s preferred measure of profits — what it calls business earnings per share at constant exchange rates — fell 9 percent in the third quarter. Profit slumped by 12.8 percent by that measure last year and in August the company said it would fall a further 7 to 10 percent this year.

Related Articles Read More >

Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals
Sanofi logo
Sanofi introduces its first digital accelerator 
Cambridge Pharma launches with UK plant in Cambridge Research Park

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards